dr reddy glp 1 Dr. Reddy's Canadian Semaglutide Launch Ignites GLP-1 Competition and stomach upset Dr. Reddy's to expand GLP-1

Subgroup analyses were conducted based on the following: Specific cancer site (e.g., colorectal, pancreatic, liver)

Heartburn and dyspepsia occur in approximately 3-9% of patients taking GLP-1 medications according to clinical trial data

Copper tripeptide and extracellular-matrix accumulation PUBMED PMID 8227353 Rat wound-chamber experiments reported increased measured extracellular-matrix accumulation after copper-tripeptide exposure

Different administration routes solve different problems

Starting Dose and Titration Schedule Retatrutide phase 2 used a structured titration: Weeks 1 to 4: 2 mg subcutaneous once weekly Weeks 5 to 8: 4 mg once weekly Weeks 9 to 12: 8 mg once weekly Week 13 onward: 12 mg once weekly (maximum dose) Gastrointestinal adverse events drove dose reductions in 15.7% of participants receiving 12 mg in the phase 2 trial